news
METIS data at ASCO Annual Meeting
Data from our positive phase 3 METIS clinical trial were presented on June 3 at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
learn moreNovocure will participate in the 2024 Wells Fargo Healthcare Conference on September 4. William Doyle, our Executive Chairman, will take part in a fireside chat at 4:30 p.m. EST, as well as one-on-one meetings with investors. Listen live on Sep 4 here: https://www.novocure.com/investor-relations/
This #WorldLungCancerDay, we thank the doctors, nurses, caregivers, patient organizations and all who support patients facing this difficult disease. #lungcancer
We reported financial results for the quarter ended June 30, 2024, including quarterly net revenues of $150 million, up 19% year-over-year, with 3,963 active patients on therapy as of June 30, up 11% compared to the same period in 2023. https://www.novocure.com/novocure-reports-second-quarter-2024-financial-results/
#earnings #NVCR
Today marks the 6th annual #GBMDay, when patients, caregivers, and advocates come together to support those living with #glioblastoma, remember those we have lost, and reaffirm our commitment to developing innovative treatments and, ultimately, a cure for this disease.
In honor of #GlioblastomaAwarenessDay (GBM Day), Mike Ambrogi, Novocure’s Senior Technology Fellow & Colin Gerner (@StacheStrong ), discussed how being present & advocating for those battling glioblastoma can impact their lives. https://vimeo.com/982768017
Glioblastoma (GBM) Awareness Day is coming up. On #GBMDay and every day, we recognize the impact of GBM, the most common primary brain cancer, on patients and caregivers. Read just a few of their stories: https://www.novocure.com/patient-experience/